Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ro 50-3821 (Mircera) Dose Response in Anemic NSCLC Patients
NCT00072059Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2003
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of Epoetin alfa RB in anemia, sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Jul 2003; status: completed.
02
Drugs
Epoetin alfa RB
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00072059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072059.